Objective
Osteoarthritis (OA) is one of the leading causes of global disability, especially among the Elderly populations – approximately 10–12% of the adult population in the world has symptomatic OA. Specifically, it affects more than 40 million people in Europe. Currently there is no cure for OA – there are no current therapies available that can reverse or halt the progression of osteoarthritis. OA's control strategy mainly consists of palliative pain treatment as there are several medicines on the market can alleviate pain and improve function in OA patients (e.g. analgesics, NSAIDs, opioids). Genis offers a revolutionary approach for the resolution of inflammation and tissue regeneration for OA patients - SIMECOS. SIMECOS is a biocompatible and bioactive drug, derived from Genis' patented food supplement BenectaTM , which provides less risk of side effects, reduced patient recovery time, protection of articular tissues, reduced scar tissue formation and increased success rate for treating OA disease.Genis' approach has been validated in a relevant environment (in vivo and in vitro studies) supported by Pre-Clinical and Phase I Clinical trials for BenectaTM, showing safety of the compound and its pronounced effect of resolution of inflammation and tissue regeneration.
Genis is a small innovative biotechnology company from Siglufjörður, Iceland, whose aim is to discover, develop and commercialize novel and life changing pharmaceutical products, supplements and medical devices derived from crustacean exoskeletons. With their novel biocompatible and bioactive drug SIMECOS they seek to disrupt the pharmaceutical market for OA's treatment, and to access a more than €45 billion market in Europe.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine rheumatology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine oncology lung cancer
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine endocrinology diabetes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
580 SIGLUFJORDUR
Iceland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.